EUVIMEDOpdag EUVIMED
EUVIMED · CrossrefJournal

Breast Cancer Research and Treatment

ISSN 0167-6806 · Springer Science and Business Media LLC

Latest articles

  1. Brain as a site of first recurrence after adjuvant therapy for early breast cancer: mining the hellenic cooperative oncology group database-The BRACE study

    Evangelia Razis, Kyriaki Papadopoulou, Nikolaos Korfiatis, Christos Christodoulou, Helen P. Kourea, Anna Goussia, Olympia Tzaida, Anna Batistatou, Andreas Mamilos, Christos Markopoulos, Vasileios Venizelos, Grigorios Xepapadakis, Pantelis Skarlos, George Pentheroudakis, Dimitrios Pectasides, Angelos Koutras, Athina Christopoulou, Amanda Psyrri, Helen Gogas, Flora Zagouri, George Fountzilas

    Published: 2026-11DOI: 10.1007/s10549-026-08085-2

  2. Real-world efficacy and safety of trastuzumab emtansine biosimilar (UJVIRA®) in early and metastatic HER2-positive breast cancer: a multicenter pooled retrospective analysis from India

    Ayesha Mahajan, Soumya Surath Panda, Lalatendu Moharana, M.V. Chandrakanth, Vivek Agarwala, Rupam Manna, S.V. Saju, Susan Honey Raju, Prasanth Ganesan, Gomathi Shankar, Ashwin Oommen Phillip, Sunu Lazar Cyriac, Anil Jose, P. Unnikrishnan, Kanu Priya Bhatia, Amit Sehrawat, Deepak Sundriyal, Himani Dhanai, Lipsita Samantaray, Swati Sucharita Mohanty, Biswajit Dubashi

    Published: 2026-11DOI: 10.1007/s10549-026-08114-0

  3. EVERolimus effectiveness after proGREssion on ENdocrine therapy plus CDK4/6 inhibitor for ER-positive/HER2-negative advanced breast cancer: EVERGREEN study

    Diogo Martins-Branco, Soraia Lobo-Martins, Philippe Aftimos, Bernardo Pereira, Leonor Vasconcelos de Matos, Leonor Fernandes, Elsa Campôa, Guilherme Nader-Marta, Michel Moreau, Donatienne Taylor, Francois P. Duhoux, Pedro Simões, Ana Rita Garcia, Vanessa Patel, Caterina Confente, Diogo Alpuim Costa, José Pereira, Catarina Santos, Marianne Paesmans, Frederico Sarmento, Teresa Gantes Padrão, Diana Simão, Daniel Bandarra, Berta Sousa, Margarida Brito, Andrea Gombos, Lieveke Ameye, Evandro de Azambuja

    Published: 2026-07DOI: 10.1007/s10549-026-08012-5

  4. External validation of PREDICT Breast v3.1 for overall survival in international cohorts, including young and invasive lobular subgroups

    Elfi M. Verheul, Frank Doornkamp, Iurii Petrov, Sabine Siesling, Hester F. Lingsma, Linetta B. Koppert, Lara W. A. Vreven, Adri C. Voogd, Maria Margarete Karsten, Lea Doppelbauer, Pimrapat Gebert, Narsis Kiani, Simona Borstnar, Paul D. P. Pharoah, Elham Hedayati, Ewout W. Steyerberg, David van Klaveren, Kasper Frank, Yassin Engelberts, Lára R. Hallsson, Toby Hackmann, Michel W. J. M. Wouters, Yufeng Liu, Uwe Siebert, Iñaki Álvarez Busto, Tamara Wit, Lennart Koch, Dirk Snelders, Anne Stiggelbout, Ida Korfage, Carlos Romero-Piqueras, Judith Rietjens, Liesbeth C. de Wreede, Daisy Monika Lal, Kathrina Dankl, Claudia Cruz Oliveira, Amara Callistus Nwosu, Teresa Puértolas

    Published: 2026-06DOI: 10.1007/s10549-026-07958-w

  5. Role of individualized intervention(s) on quality of life and adherence to adjuvant endocrine therapy in premenopausal women with early-stage breast cancer: MyCHOICE study

    Shahid Ahmed, Sonya Mannala, Prosanta Mondal, Wardah Mahmood, Haji Ibrahim Chalchal, Lynn Dwernychuk, Nayyer Iqbal, Muhammad Salim, Muhammad Imtiaz Khan, Osama Ahmed, Mita Manna, Donelda Gowan Leverick, Ambika Chandrasekhar, Ayesha Bashir, Kamal Haider, Anne Leis, Saija Kontulainen, Amer Sami

    Published: 2026-06DOI: 10.1007/s10549-026-07999-1

  6. Long-term outcomes of eribulin‑based neoadjuvant chemotherapy for triple‑negative breast cancer patients stratified by homologous recombination deficiency status: results of the randomized JBCRG-22 study

    Norikazu Masuda, Hiroyuki Yasojima, Hiroko Bando, Takashi Yamanaka, Hideo Shigematsu, Masato Takahashi, Shigenori E. Nagai, Mitsuya Ito, Tomoyuki Aruga, Mariko Tokiwa, Shigeru Imoto, Rikiya Nakamura, Hiroshi Ishiguro, Hidetaka Kawabata, Shigehira Saji, Hironori Haga, Satoshi Morita, Masakazu Toi

    Published: 2026-04DOI: 10.1007/s10549-026-07917-5

Volumes

2026 · 2092025 · 3552024 · 3732023 · 3352022 · 3682021 · 4742020 · 4752019 · 4732018 · 4742017 · 4532016 · 3702015 · 4382014 · 4262013 · 4622012 · 6882011 · 6442010 · 5962009 · 4432008 · 3542007 · 2832006 · 2512005 · 2452004 · 2032003 · 2672002 · 2162001 · 1842000 · 1621999 · 1751998 · 1791997 · 1361996 · 1661995 · 1251994 · 1421993 · 1411992 · 1101991 · 1311990 · 891989 · 681988 · 791987 · 69

Viden, der passer til dit arbejde.

Fra en gratis start over personlig litteratursøgning til den komplette Research Suite.

Se priser →

Er alle forlagsfuldtekster inkluderet?

Nej. Bibliografiske referencer, abstracts og fuldtekster er forskellige typer indhold. Om en fuldtekst er tilgængelig, afhænger af kilden, Open Access og dine eksisterende licenser. Et EUVIMED-abonnement erstatter ikke yderligere forlagsrettigheder.